Efficient therapy of @entity75 with VEGF121-fibrin in an animal model of XXXX .

@entity46455 @entity75 @entity1066 @entity35320 @entity35319 @entity1573 @entity59257 @entity272 @entity785
BACKGROUND: In @entity785 ( @entity785 ), chronic and uncontrolled overexpression of @entity35320 ( @entity35320 ) results in chaotic vessels, and intractable fingertip @entity1066 . Vice versa, @entity35320 is a potent mediator of angiogenesis if temporally and spatially controlled. We have addressed this therapeutic dilemma in @entity785 by a novel approach using a VEGF121 variant that covalently binds to fibrin and gets released on demand by cellular enzymatic activity. Using University of California at Davis (UCD)-206 @entity1573 , we tested the hypothesis that cell-demanded release of fibrin-bound VEGF121 leads to the formation of stable blood vessels, and clinical improvement of @entity75 . METHODS: Ninety-one early and late @entity272 of UCD-206 @entity1573 were treated locally with VEGF121-fibrin, fibrin alone, or left untreated. After 1   week of treatment the clinical outcome was assessed. Angiogenesis was studied by immunofluorescence staining of vascular markers quantitatively analysed using TissueQuest. RESULTS: Overall, 79.3% of the lesions treated with VEGF121-fibrin showed clinical improvement, whereas 71.0% of fibrin treated controls, and 93.1% of untreated lesions deteriorated. This was accompanied by significantly increased growth of stable microvessels, upregulation of the proangiogenic @entity35319 and its regulator @entity59257 , and increase of endogenous endothelial @entity35320 expression. CONCLUSIONS: Our findings in the avian model of @entity785 suggest that cell-demanded release of VEGF121 from fibrin matrix induces controlled angiogenesis by differential regulation of @entity46455 and @entity35319 expression, shifting the balance towards the proangiogenic @entity35319 . The study shows the potential of covalently conjugated @entity35320 -fibrin matrices for the therapy of @entity75 such as fingertip @entity1066 .
